Rationale: In a modified methacholine provocation test that was used to study changes in airway responsiveness to occupational irritants or sensitizers in healthy subjects, two protocols were used: a long protocol (doubling methacholine concentrations between dose steps) or a short protocol (fourfold increases in concentration). This modified methacholine provocation allows measurements of the provocative dose causing 20% decrease in FEV 1 (PD 20 ) in a high proportion of a normal population. Methods: The distribution of PD 20 was investigated in healthy nonatopic men without history of allergy or asthma symptoms using the long protocol (n ‫؍‬ 101) or the short protocol (n ‫؍‬ 309). In addition, 30 healthy subjects underwent methacholine provocation tests using both protocols. Results: PD 20 was defined in 79% of subjects with the long protocol and in 48% of subjects with the short protocol. The provocative concentration of methacholine causing a 20% decline in FEV 1 (PC 20 ) and PD 20 were significantly lower using the long protocol: long-protocol PC 20 (median [25th to 75th percentile]), 19.9 mg/mL (3.9 to > 32 mg/mL) compared with short-protocol PC 20 , > 32 mg/mL (8.7 to >32 mg/mL; p < 0.0001); long-protocol PD 20 , 4.2 mg (1.6 to 20 mg) compared with short-protocol PD 20 , > 13.7 (2.6 to > 13.7 mg; p ‫؍‬ 0.006). The differences in PD 20 using short and long protocols were confirmed in a randomized trial of 30 healthy subjects tested with both protocols. Conclusion: Using doubling concentrations, PC 20 and PD 20 could be defined in a higher proportion of healthy subjects than a protocol using fourfold dose increases. Furthermore, the doubling protocol results in a PD 20 estimate that is less than half the value obtained when using a protocol with fourfold concentrations between dose steps. The difference remains, whether the methacholine effect is regarded as cumulative or noncumulative. The explanation for the difference between the protocols is unclear.
B
ronchial responsiveness is often assessed by bronchial provocation tests using direct stimuli such as methacholine or histamine. Administration of the bronchoconstrictor is commonly conducted with a dosimeter or a tidal breathing method. Inspiratory flow and inhaled dose of the agent are poorly controlled in most methods that have become standard in the clinical evaluation of asthma. 1, 2 The methods of Orehek et al 3 and Eiser et al, 4 as distinguished from other methods, includes control of the inspired volume and flow, and drying of the nebulized solution, resulting in a reduction of the pharyngeal deposition.
In all these methods, repeated deep inspirations are performed when the agent is inhaled and/or when forced expirations are made in order to measure FEV 1 . Previously it has been demonstrated that the decrease in FEV 1 caused by administration of a bronchoconstricting agent is attenuated for up to 10 min by a deep inhalation performed before or after administration of the agent. 5 Shortening the protocol by reducing the time interval between dose steps reduces the time interval between the deep inhalations required to measure FEV 1 , which therefore influences the outcome of the FEV 1 recorded at the next dose step.
In order to study changes in bronchial responsiveness induced by occupational irritants or sensitizers in symptom-free subjects, we have designed a modified protocol, based on a previously described method. In this methacholine-provocation protocol, deep inhalations are minimized and the dose delivered to the lower airways is controlled. 6 Using this method, a high proportion of healthy subjects reacts with a Ն 20% decrease in FEV 1 . Furthermore, this method discriminates between exposed and nonexposed subjects in several occupational settings. [7] [8] [9] [10] [11] [12] With our method, the nebulized solution is dried prior to inhalation, which reduces the size of the droplets and increases the deposition of methacholine in the lower airways. Flow and time of inhalation, and inhaled dose are controlled, and only one deep inhalation (FEV 1 measurement) is performed at each dose step.
The duration of a standard bronchial provocation test with doubling doses of methacholine usually is 30 to 60 min. In studies with large numbers of subjects, a more rapid method would be useful. We therefore modified the test for healthy nonasthmatic subjects by using fourfold increases of the methacholine concentration rather than doubling doses. It was, however, not clear whether or not the outcome of the bronchial provocation test would be the same for the two provocation protocols.
Data obtained from different studies in working populations were compiled in order to elucidate the comparability of the two protocols (doubling and fourfold increases of the concentration).
Materials and Methods
Two methacholine provocation protocols were used. The standard protocol (the long protocol) employed doubling concentrations of methacholine, starting at 0.5 mg/mL, followed by doubling concentrations until a fall in FEV 1 of Ն 20% or a concentration of 64 mg/mL was reached. The short protocol was identical, with one exception: the methacholine concentration was increased in fourfold steps up to the highest concentration (32 mg/mL).
The bronchial provocation tests were performed as parts of a number of studies in different working and healthy referral populations. Details about the studies have been published previously ( Table 1) . Subjects with the diagnosis of asthma or a history of other chronic lung diseases were excluded.
Nonatopic Men
Nonatopic men (n ϭ 410) 38 years of age (range, 19 to 78 years) with no history of asthma or other lung disease, or allergic disease, and with negative skin-prick test result or negative Phadiatope (Pharmacia; Uppsala, Sweden) test result participated in the study. This group was selected to avoid possible influences of sex and atopy on the outcome of the two protocols. The long protocol was used in 101 men and the short protocol in 309 men.
Randomized Trial
Since the long and short protocols were studied in different subjects, a randomized trial in 30 healthy nonsmoking volunteers (12 women) with no history of atopy or asthma (mean age, 37 years; range, 21 to 61 years) using both the long and short protocols was performed. The two methacholine tests were performed 1 to 2 weeks apart in random order. Characteristics of the different groups are given in Table 2 . The project was approved by the ethics committee at the Karolinska Institute, and all subjects gave their informed consent
Spirometry
Spirometry was performed with a wedge spirometer (Vitalograph; Buckingham, UK). The highest of three reproducible measurements (the two highest within 5%) of FEV 1 and FVC maneuvers were selected as baseline values.
Methacholine Test
The methacholine test commenced 5 to 10 min after the spirometry. Following inhalation of the diluent, increasing con- centrations of methacholine were inhaled at exactly 6-min intervals, ie, 6 min from the start of one inhalation to the start of the next inhalation, until FEV 1 had decreased by 20% or the highest concentration was reached. The methacholine concentrations were 0.5, 1, 2, 4, 8, 16, 32, and 64 mg/mL (long protocol) or 0.5, 2, 8, and 32 mg/mL (short protocol). The highest concentrations of methacholine given in the two protocols were 32 mg/mL and 64 mg/mL, which corresponds to a cumulated dose of 8.5 mg (43 mol/L) and 25.5 mg (130 mol/L), respectively, at a nebulizer output of 0.4 mg/min. The inhalation flow (0.4 L/s), inhalation time (2 s) and exhalation time (2 s), volume (0.8 L), and the number of breaths (15 breaths, guided by the pace of a metronome) were controlled during the provocation procedure that lasted for exactly 1 min. Only one FEV 1 measurement was performed at each dose step 4 min after the start of inhalation. 5 If this measurement was technically unsatisfactory (on rare occasions), the next dose was given only if no symptoms were reported. The subjects were instructed not to take deep breaths and to avoid coughing during the entire procedure, including the time between the spirometry and start of the methacholine test.
The methacholine was continuously administered with a jet nebulizer (Astra Meditec; Gothenburg, Sweden) in the nonatopic men group and with a Sidestream nebulizer (Medic-Aid; Pagham, UK) in the randomized trial. The jet nebulizer used dry compressed air (390 kPa) producing an aerosol of 0.1 L/s. The system was supplied with additional dry air (0.3 L/s) that was led through a drying device. 6 In the Sidestream nebulizer, all air (0.4 L/s) was led through the nebulizer. The nebulizate was led through a metal device (3.4 L), where the aerosol was dried for about 8 s before inhalation. The volume output of the nebulizers was measured as weight loss after 1 min of nebulization, and the different nebulizers were calibrated every day. A correction was applied in order to convert volume output (including water used to humidify air passing the nebulizer) into the amount of methacholine that leaves the nebulizers. This correction was 0.928 for the jet nebulizer and 0.75 for the Sidestream nebulizer (where four times more air passes through the nebulizer). The correction factors were calculated from measurements of concentration increase in the nebulizer solution and from comparison of methacholine responses. 13 PC 20 is the estimated provocative concentration of methacholine causing a 20% decrease in FEV 1 compared to the value measured after inhalation of the diluent. The value was calculated by interpolation using the first FEV 1 Յ 80% of the postdiluent value and the preceding FEV 1 on a logarithmically transformed methacholine concentration scale. The provocative dose of methacholine causing a 20% decline in FEV 1 (PD 20 ; the cumulated dose) was calculated in a corresponding fashion, using logarithms of the cumulated doses rather than concentrations of methacholine. The dose was calculated from the corrected nebulizer output and the methacholine concentration in the nebulizer.
A dose-response slope (DRS) was calculated as the percent change in FEV 1 as a function of the cumulated methacholine dose and was calculated by linear regression using all measure points, the first point representing the mean value of the preexposure and postdiluent values. This method differs from the previously reported methods when only the end point (ie, the last value) is considered. 14 -18 All calculations of PC 20 , PD 20 , and DRS were made using appropriate algorithms in a datasheet (Excel; Microsoft; Redmond, WA). Because of the difference in concentrations of methacholine in the two protocols, the number of subjects who reacted with Ͼ 20% decrease in FEV 1 at a cumulated dose of Յ6 mg methacholine was calculated.
Atopy was assessed by skin-prick test with a standard panel with the 10 most common allergens in Sweden (Pharmacia; Uppsala, Sweden and ALK; Copenhagen, Denmark) or with Phadiatope (n ϭ 228). 
Statistics

Results
Nonatopic Men
PC 20 was defined in 80 of 101 subjects (79%) who underwent the long protocol and 150 of 309 subjects (48%) using the short protocol (p ϭ 0.01; Fig 1) . PC 20 and PD 20 were significantly lower when the long protocol was used than when the methacholine concentration was increased in fourfold concentration steps (p Ͻ 0.0001 and p ϭ 0.0006, respectively; Fig 1 and Table 3 ) The DRS did not differ significantly between the two protocols (p ϭ 0.15). There was a slight DRS difference in the middle part of the cumulative frequency of curve (Fig 1, bottom, c, and Table 3 ). Fifty-nine percent of the subjects using the long protocol and 43% using the short protocol had Ն 20% fall in FEV 1 at cumulated methacholine dose of 6 mg (31 mol/L; p ϭ 0.01; Table 3 ).
Randomized Trial
In the randomized trial, four of the subjects did not reach a 20% decrease in FEV 1 when performing the long protocol. The corresponding number when performing the fourfold increases in methacholine concentrations was 12 subjects (p Ͻ 0.01; Fig 2, 3) .
PC 20 and PD 20 were significantly lower using the long protocol than using the short protocol (p ϭ 0.008 and p ϭ 0,04, respectively; Fig 2, top, a,  and middle, b) . The DRS differed significantly between the two protocols (p ϭ 0.01; Fig 2, bottom, c) . The differences between the two techniques were calculated in 26 subjects (the 4 subjects who did not have a Ͼ 20% decrease in FEV 1 in either provocation protocol were excluded from the comparison).
Eighteen of 30 subjects (60%) reacted with a 20% FEV 1 decrease after an inhaled dose of 6 mg (31 mol/L) methacholine when performing doubling increases. The corresponding number using the short protocol was 7 of 30 subjects (23%; p ϭ 0.009; Table 3 ).
Discussion
The present study demonstrates that the protocol using fourfold increases in methacholine concentra- 
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Clinical Investigations tions results in apparently lower bronchial sensitivity to methacholine, compared to the standard doubling doses protocol as assessed by PC 20 or PD 20 in healthy subjects. It has been previously shown that methacholine has a small cumulative effect. 19 In the present study, the discrepancy between the two protocols remains also if the dose is expressed as cumulated inhaled dose. The difference between the two protocols is thus not depending on whether the bronchial effect is regarded as cumulative or noncumulative.
The finding of the difference between the long and short protocols is intriguing, and we have no convincing explanation. The difference between the groups is smaller if provocative dose rather than provocative concentration values were used, suggesting that a cumulative degree of airway provocation is a better estimate of the dose than the provocative concentration values. The difference between the protocols cannot be explained by overestimation of the cumulative dose, since the duration of the long test is longer than the fourfold increase test. It could be assumed that the effect of the first methacholine doses starts to decline during the provocation procedure, but this would lead to even lower PD 20 in the fourfold protocol than when doses are doubled. When plotting FEV 1 change over log concentration of methacholine (or cumulated dose), a curvilinear relation was found. If the two points before and after crossing the 80% of basal FEV 1 line are wider separated on the x-axis (as is the case for the short protocol compared to doubling dose increases), the intersection with the 80% FEV 1 line would tend to move to the left with fourfold increases (ie, suggest- ing more sensitive airways, which is the opposite to the finding of the present study). Thus, the discrepancy between the protocols does not seem to be explained by an artifact based on the way provocative concentration or provocative dose values were calculated. Airway hyperresponsiveness is influenced by atopy and airway caliber, but also by factors such as sex, age, and smoking. 20 Since different subjects underwent the twofold and the fourfold test, it cannot be excluded that true differences in responsiveness between the groups partly explain the findings. However, the results in the randomized trial, in which the same subjects underwent both protocols, contradict such an interpretation since the differences between the protocols remained. A deep inhalation shortly before the inhalation of methacholine influences the airways and the FEV 1 reduction after inhalation of methacholine is attenuated, compared to the situation in which deep inhalations before methacholine are avoided. This effect lasts for 6 to 10 min. Repeated deep inhalations after inhalation of methacholine also attenuate the FEV 1 response, however, less effectively than a deep inhalation performed in relaxed airways, shortly before administration of the methacholine. 5, 21 It is thus possible that in the short protocol, the effect of the previous doses is less and the smooth muscles are less contracted before the dose when FEV 1 decreases Ն 20%, than in the long protocol. We suggest that this difference may depend on the fact that there are fewer inhaled doses to reach the same dose in the short protocol than in the long protocol. The magnitude of such an effect is, however, unclear, and other mechanisms yet unknown may also contribute to the observed effects.
In conclusion, the difference between the two protocols emphasizes the importance to strictly adhere to a given protocol, using doubling or fourfold increasing dose steps, avoiding mixtures between the two protocols. For results to be comparable also, the time between dose steps must be constant and strictly adhered to. The long protocol is the most preferable method to assess changes and differences in bronchial responsiveness, because of smaller differences in methacholine concentration between the different dose steps. Therefore, the long protocol may be more useful in research. However, for clinicians who want to discriminate between asthma and nonasthmatic conditions, the short protocol may be equally useful. This was, however, not examined in the present study.
